Degner, Detlef

[["dc.bibliographiccitation.firstpage","560"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","International Journal of Neuropsychopharmacology"],["dc.bibliographiccitation.lastpage","573"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Toto, Sermin"],["dc.contributor.author","Grohmann, Renate"],["dc.contributor.author","Bleich, Stefan"],["dc.contributor.author","Frieling, Helge"],["dc.contributor.author","Maier, Hannah B"],["dc.contributor.author","Greil, Waldemar"],["dc.contributor.author","Cordes, Joachim"],["dc.contributor.author","Schmidt-Kraepelin, Christian"],["dc.contributor.author","Kasper, Siegfried"],["dc.contributor.author","Stübner, Susanne"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Druschky, Katrin"],["dc.contributor.author","Zindler, Tristan"],["dc.contributor.author","Neyazi, Alexandra"],["dc.date.accessioned","2020-12-10T18:19:17Z"],["dc.date.available","2020-12-10T18:19:17Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1093/ijnp/pyz037"],["dc.identifier.eissn","1469-5111"],["dc.identifier.issn","1461-1457"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16947"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75188"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/17087 but duplicate"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.subject.ddc","610"],["dc.title","Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","483"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","488"],["dc.bibliographiccitation.volume","261"],["dc.contributor.author","Degner, Detlef"],["dc.contributor.author","Nitsche, Michael A."],["dc.contributor.author","Bias, Frank"],["dc.contributor.author","Ruether, Eckart"],["dc.contributor.author","Reulbach, Udo"],["dc.date.accessioned","2018-11-07T08:50:54Z"],["dc.date.available","2018-11-07T08:50:54Z"],["dc.date.issued","2011"],["dc.description.abstract","The aim of this naturalistic observational study was to investigate EEG alterations in patients under olanzapine treatment with a special regard to olanzapine dose and plasma concentration. Twenty-two in-patients of a psychiatric university ward with the monodiagnosis of paranoid schizophrenia (ICD-10: F20.0), who received a monotherapy of olanzapine were included in this study. All patients had a normal alpha-EEG before drug therapy, and did not suffer from brain-organic dysfunctions, as verified by clinical examination and cMRI scans. EEG and olanzapine plasma levels were determined under steady-state conditions (between 18 and 22 days after begin of treatment). In 9 patients (40.9%), pathological EEG changes (one with spike-waves) consecutive to olanzapine treatment were observed. The dose of olanzapine was significantly higher in patients with changes of the EEG than in patients without changes (24.4 mg/day (SD: 8.1) vs. 12.7 mg/day (SD: 4.8); T = -4.3, df = 21, P < 0.001). In patients with EEG changes, the blood plasma concentration of olanzapine (45.6 mu g/l (SD: 30.9) vs. 26.3 mu g/l (SD: 21.6) tended to be also higher. The sensitivity of olanzapine dosage to predict EEG changes was 66.7%, the specificity 100% (Youden-index: 0.67). EEG abnormalities during olanzapine treatment are common. These are significantly dose dependent. Thus, EEG control recordings should be mandatory during olanzapine treatment with special emphasis on dosages exceeding 20 mg per day, although keeping in mind that EEGs have only a limited predictive power regarding future epileptic seizures."],["dc.identifier.doi","10.1007/s00406-011-0208-4"],["dc.identifier.isi","000297619700005"],["dc.identifier.pmid","21431467"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7318"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21800"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Heidelberg"],["dc.relation.issn","0940-1334"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","EEG alterations during treatment with olanzapine"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]